RPG Life Sciences profitability ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY22 and earlierAlpha Plus
Returns
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
20.3%20.3%
15.9%15.9%
21.5%21.5%
16.2%24.0%
Margins
20.5%20.8%
17.8%17.8%
19.3%21.8%
14.5%16.3%
−1.3%−1.3%
Additional
24.9%25.3%
—34.5%
20.3%13.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

RPGLIFE₹2,844.00

RPG Life Sciences Limited

· Pharma & Health
₹ CrorePeersGUFICBIOGUJTHEMUNICHEMLABORCHPHARMASMSPHARMAFDCIOLCPINDSWFTLABMcap ₹4,703 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Returns
Return on Common Equity———20.2820.28
Return on Assets———15.8815.88
Return on Capital Employed———21.4621.46
Return on Invested Capital———23.9916.21
Margins
EBITDA Margin———20.7920.45
Operating Margin———17.7517.75
Pretax Margin———21.7919.34
Net Income Margin———16.2814.53
FCF Margin———-1.25-1.25
Additional
Effective Tax Rate———25.3124.90
Dvd Payout Ratio———34.46—
Sustainable Growth Rate———13.2920.28
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.